Subscribe
shutterstock_1878287359_mats_wiklund
Mats Wiklund / Shutterstock.com
22 July 2021GenericsRory O'Neill

AstraZeneca loses major generics appeal in India

The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Indian court rejects AstraZeneca’s injunction request
24 November 2020   The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
Americas
AstraZeneca prevails in inhaler dispute
9 March 2021   AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.
Americas
Mylan gets Fed Circ reprieve in inhaler dispute
9 December 2021   Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Indian court rejects AstraZeneca’s injunction request
24 November 2020   The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
Americas
AstraZeneca prevails in inhaler dispute
9 March 2021   AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.
Americas
Mylan gets Fed Circ reprieve in inhaler dispute
9 December 2021   Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

More on this story

Big Pharma
Indian court rejects AstraZeneca’s injunction request
24 November 2020   The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
Americas
AstraZeneca prevails in inhaler dispute
9 March 2021   AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.
Americas
Mylan gets Fed Circ reprieve in inhaler dispute
9 December 2021   Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner